๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma

โœ Scribed by Giovanni L. Ceresoli; Stefania Dell'Oro; Paolo Passoni; Eugenio Villa

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
90 KB
Volume
89
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II study of patients with metastat
Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion
โœ William J. Tester; Pamela Y. Jin; Deborah H. Reardon; Jeffrey B. Cohn; Martin H. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 77 KB ๐Ÿ‘ 2 views

## METHODS. Twenty patients with histologically proven Stage IV NSCLC were en-Pennsylvania. rolled in this study. All were treated on an outpatient basis with standard premedication followed by paclitaxel 200 mg/m 2 infused intravenously over 3 hours. Treatments were repeated every 21 days for a

Vinorelbine in elderly patients with ino
Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma : A Phase II study
โœ Gianfranco Buccheri; Domenico Ferrigno ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 109 KB ๐Ÿ‘ 2 views

## BACKGROUND. Cancer in the elderly is becoming a complex and frequent issue. At least 30% of lung carcinomas are expected to arise each year in elderly patients, who often have significant comorbidity. The most appropriate treatment for this large portion of cancer patients remains unknown. The

A phase II study of paclitaxel plus carb
A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma
โœ Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hart ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 96 KB ๐Ÿ‘ 1 views

## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi